Following the EMPEROR-Preserved and FIGARO-DKD data readouts at ESC 2021, it seems as if a deal for Lexicon’s sotagliflozin should be building momentum. Below, FENIX provides thoughts on the quickly evolving HF/CKD market and insight into what a potential deal for sotagliflozin may look like, despite some caveats.
Two cardiometabolic-related news items have been observed: Lexicon announced the presentation of additional analyses from the SOLOIST and SCORED Ph3 trials at the ESC 2021 Digital Experience; and Amarin announced the on-demand, Late Breaking Science Presentation at ESC 2021 of data from the prior MI subgroup analysis of its Vascepa/Vazkepa (icosapent ethyl) Ph3 REDUCE-IT study. Of note, the full ESC 2021 conference takes place August 27-30. Below, FENIX provides highlights and insights for the respective news items.
Lexicon participated in the 2020 Stifel Virtual Healthcare Conference and provided brief updates on its sotagliflozin strategy following the data readout from SOLOIST and SCORED. In case you missed it, here is a link to FENIX’s initial thoughts on the data. Below, FENIX provides highlights from Lexicon senior management’s commentary as well as an updated perspective and implications to sotagliflozin’s commercial prospects.
Today, Lexicon announced that Sanofi and Lexicon have amicably settled their differences in the termination of their collaboration for sotagliflozin. The settlement includes Sanofi to pay Lexicon $208M up front with the balance of $52M to be paid within 12 months ($260M total). Below, FENIX provides thoughts and perspective from the press release and the associated investor call.
Lexicon hosted its Q2 ’19 earnings call and provided updates to its business including commentary on Sanofi’s recent decision to end the sotagliflozin partnership. Below, FENIX provides highlights and insights from the call.
Today, the FDA published a notice in the Federal Register announcing the sotagliflozin adcom for Jan 17, which was press released yesterday by Lexicon. No notable new details were provided, and the proposed indication is in-line with expectations as “…Adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus.”